Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

NCT02803203 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
EGFR-mutant Lung Cancers

Interventions

DRUG: osimertinib
DRUG: Bevacizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]